You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Safe, Large-Format Lithium Ion Batteries for Aircraft

    SBC: Yardney Technical Products, Inc.            Topic: AF141071

    YTP will develop technology that provides a high performance, modular Li-ion battery with: redundant safety features, safer thin, metal case cell designs; fin/micro-channel thermal control system; and an evaporating fluid system that rapidly quenches failing cells to prevent thermal runaway and fratricide. The end goal of the proposal is making a lighter, longer lasting, less expensive, safer JSF ...

    SBIR Phase I 2014 Department of DefenseAir Force
  2. A Pintle-Free Divert and Attitude Control System

    SBC: Digital Solid State Propulsion, Inc            Topic: AF141137

    ABSTRACT: Digital Solid State Propulsion is proposing to develop a Divert and Attitude Control System (DACS) for tactical air superiority missiles, using proprietary Electric Solid Propellants (ESPs). Unlike conventional propellants, ESPs can be ignited with electric power applied through inert electrodes within the propellant grain itself, while also maintaining a higher level of insensitivity. ...

    SBIR Phase I 2014 Department of DefenseAir Force
  3. Electrically Responsive Energetics for Variable Yield Weapons

    SBC: Digital Solid State Propulsion, Inc            Topic: AF141145

    ABSTRACT: Digital Solid State Propulsion is proposing to develop an Electrically Variable Explosive (EVE) which, through direct electrical control, will provide on-demand sensitization and throttling for enhanced energy output in explosive fills. EVEs are based upon DSSP"s Electric Solid Propellant (ESP) Technology which has demonstrated modified burning rates with electrical input, on/off operat ...

    SBIR Phase I 2014 Department of DefenseAir Force
  4. Modular, Low Cost Fixture for Evaluating OML Treatments for Stress-Strain Loading During Environmental Conditioning

    SBC: Material and Process Solutions, LLC            Topic: AF141167

    ABSTRACT: Material and Process Solutions propose to develop a modular stress-strain fixture for gap fillers and OML coating treatments in Phase I of this SBIR program. This fixture will combine the best attributes of various weapon systems custom gap assembly systems to one or two gap geometry standards. The modular design of the fixture(s) will be combined with an electromagnetic degradation ef ...

    SBIR Phase I 2014 Department of DefenseAir Force
  5. Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment

    SBC: CALISTA THERAPEUTICS INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled n ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Inter-alpha-inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Neonatal hypoxia-ischemia (HI) remains a major cause of acute perinatal brain injury, leading ultimately to neurologic dysfunction manifesting as cerebral palsy, mental retardation, and epilepsy. Cerebral oxygen deprivation and/or reduced blood flow due to umbilical cord occlusion, prolonged labor, and/or intracranial hemorrhage produce an inflammatory respons ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSIS

    SBC: ENDURX PHARMACEUTICALS INC            Topic: NCI

    DESCRIPTION (provided by applicant): Glioblastoma multiforme (GBM) or glioblastoma, is the most common and aggressive malignant primary brain tumor in humans. An effective treatment that increases patient survival would represent a significant advance inthe field, and provide a desperately needed new therapy for this deadly disease. EnduRx is focused on the development of new, targeted systems f ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. IGF::OT::IGF High-Impact Substance Abuse Prevention Technologies. SBIR Phase I. Period of Performance 7/16/2014-1/15/2015

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NIDA

    The overarching objective of this project is to develop an innovative technological tool that will facilitate the implementation of an evidence-based substance abuse prevention program and related health behavior risk programs among military personnel. PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Point-of-care immunoassay for early diagnosis of pertussis

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION provided by applicant Pertussis is a serious and potentially life threatening respiratory disease caused by the bacterium Bordetella pertussis Worldwide million people become ill with pertussis each year and of these patients die Despite high vaccine coverage in the United States there were still over pertussis cases reported in the U S in Rapid diagn ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government